Circio Holding (LSE:0RIS) - Stock Price, News & Analysis

0RIS Stock Overview

A biotechnology company, develops novel circular RNA and immunotherapy medicines. More details

0RIS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings are forecast to grow 86.5% per year

Risk Analysis

Does not have a meaningful market cap (NOK56M)

Makes less than USD$1m in revenue (NOK10M)

Negative shareholders equity

Shares are highly illiquid

+ 2 more risks

Circio Holding ASA Competitors

Theracryf

AIM:TCF

UK£2.3m

BSF Enterprise

LSE:BSFA

UK£3.4m

Genflow Biosciences

LSE:GENF

UK£6.3m

Verici Dx

AIM:VRCI

UK£8.2m

Price History & Performance

Summary of all time highs, changes and price drops for Circio Holding
Historical stock prices
Current Share Price	NOK 11.20
52 Week High	NOK 37.20
52 Week Low	NOK 11.12
Beta	2.06
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-96.14%
5 Year Change	-95.71%
Change since IPO	-96.27%

Recent updates

Shareholder Returns

	0RIS	GB Biotechs	GB Market
7D	0%	-6.0%	-0.3%
1Y	n/a	-22.4%	6.1%

Return vs Industry: Insufficient data to determine how 0RIS performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0RIS performed against the UK Market.

Price Volatility

Is 0RIS's price volatile compared to industry and market?
0RIS volatility
0RIS Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.5%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0RIS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0RIS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	17	Erik Wiklund	www.circio.com

Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system.

Circio Holding ASA Fundamentals Summary

How do Circio Holding's earnings and revenue compare to its market cap?
0RIS fundamental statistics
Market cap	NOK 56.45m
Earnings (TTM)	-NOK 449.26m
Revenue (TTM)	NOK 10.00m

5.6x

P/S Ratio

-0.1x

P/E Ratio

Is 0RIS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RIS income statement (TTM)
Revenue	NOK 10.00m
Cost of Revenue	NOK 0
Gross Profit	NOK 10.00m
Other Expenses	NOK 459.26m
Earnings	-NOK 449.26m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Feb 15, 2024

Earnings per share (EPS)	-62.71
Gross Margin	100.00%
Net Profit Margin	-4,491.69%
Debt/Equity Ratio	-135.9%

How did 0RIS perform over the long term?

See historical performance and comparison

0RIS Stock Overview

Rewards

Risk Analysis

Circio Holding ASA Competitors

AIM:TCF

UK£2.3m

LSE:BSFA

UK£3.4m

LSE:GENF

UK£6.3m

AIM:VRCI

UK£8.2m

Price History & Performance

Recent News & Updates

Circio Holding ASA Presents Circvec Circular RNA in Vivo Expression Proof-Of-Concept Data At ESGCT 2024 Annual Meeting

Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 60 million.

Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus

Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University

Circio Holding ASA, Annual General Meeting, Jun 05, 2024

Recent updates

Circio Holding ASA Presents Circvec Circular RNA in Vivo Expression Proof-Of-Concept Data At ESGCT 2024 Annual Meeting

Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 60 million.

Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus

Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University

Circio Holding ASA, Annual General Meeting, Jun 05, 2024

IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration

Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital

New major risk - Financial position

High number of new directors

New major risk - Negative shareholders equity

High number of new directors

High number of new directors

Forecast to breakeven in 2024

High number of new directors

High number of new directors

Targovax Announces That the TG01 Study in Multiple Myeloma At Oslo University Hospital Has Received Regulatory Approvals to Proceed

Targovax ASA to Report Q4, 2023 Results on Feb 15, 2024

No longer forecast to breakeven

High number of new directors

Targovax ASA Completes ONCOS-102 Phase 1b Study in PD-1 CPI Resistant Advanced Melanoma Has Been Published in the Oncology Journal Clinical Cancer Research

No longer forecast to breakeven

High number of new directors

Targovax ASA Receives Approval to Proceed with the Oncos-102 Phase 2 Melanoma Study from the US FDA

No longer forecast to breakeven

High number of new directors

High number of new directors

Targovax ASA Announces that the FDA Grant Authorization to Initiate Clinical Trials with the Enhanced TG01 RAS Vaccine in the USA

High number of new directors

Targovax ASA Announces Board Changes

High number of new directors

Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022

Targovax ASA Announces ONCOS-102 Achieves 25.0 Months Median Overall Survival in First Line Mesothelioma

Chief Executive Officer recently bought kr201k worth of stock

High number of new directors

High number of new directors

Chief Financial Officer Torbjørn Furuseth has left the company

High number of new directors

Targovax Receives Fast Track Designation for Oncos-102 in Melanoma

Targovax Announces Completed Enrollment in the Phase 1/2 Trial with ONCOS-102 in Combination with Durvalumab in Patients with Advanced Colorectal Cancer with Peritoneal Malignancies

Targovax ASA's ONCOS-102 Mesothelioma 24-Month Data Shows Class-Leading Median Overall Survival

Targovax ASA Announces Board Changes

Targovax Granted US Patent for Oncos-102 in Combination with Checkpoint Inhibitors

Continued Survival Benefit in Targovax's ONCOS-102 Trial in Mesothelioma At the 21-Month Follow-Up

Targovax ASA Receives Fast-Track Designation for ONCOS-102

Targovax ASA and Papyrus Therapeutics Enter Research Collaboration to Develop Novel ONCOS Viruses with Receptor Tyrosine Kinase (RTK) Inhibitor Functionality

Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore

Shareholder Returns

Price Volatility

About the Company

Circio Holding ASA Fundamentals Summary

5.6x

-0.1x

Earnings & Revenue